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Introduction
Hypophosphatemia hasmany heritable or acquired causes.
(1)
Pediatric and adult bone specialists with experience in rare
diseases are accustomed to managing patients with X-linked
hypophosphatemia (XLH). However, autosomal dominant hypo-
phosphatemia (ADH) is much less common; even large meta-
bolic bone centers often have little to no clinical experience in
managing this disorder. Despite being caused by defects in
two different genes (PHEX versus FGF23, respectively), XLH and
ADH have in common the excessive serum concentrations of
the hormone ﬁbroblast growth factor 23 (FGF23). FGF23 excess
results in renal phosphate loss with subsequent hypophosphate-
mia, muscle weakness, and impaired mineralization. Such hypo-
mineralization affects (i) hypertrophic chondrocytes in the
growth plates, leading to rickets; (ii) newly formed osteoid dur-
ing modeling and remodeling, leading to osteomalacia; and
(iii) teeth, leading to taurodontism with thin enamel layer and
dentinal defects.
Historical terminology is still being used in the bone ﬁeld.
Genetic disorders should not be named after their childhood
manifestation (rickets) but carry an ageless name. Therefore,
similar to XLH (which previously included “Rickets”, XLHR), we
chose to use ADH (not ADHR) for a condition that affects more
than just growth plates.
Despite similar phenotype and complications from FGF23
excess, treatment studies have only been conducted in XLH
and not ADH. In particular the FGF23 antibody burosumab(2)
is licensed for use in XLH, but not for use in ADH, or any other
rare condition with FGF23 excess. However, recent advances
in the understanding of ADH pathophysiology suggest a
new therapeutic, and in fact also preventative, option for the
renal loss of the element phosphorus (P, atomic number 15)
in individuals with ADH: the element iron (Fe, atomic
number 26).
Unraveling the Mechanism of Disease: the
Interplay of Elements
In 1958, Winters and colleagues(3) documented dominant inher-
itance of hypophosphatemic rickets, apparently the ﬁrst descrip-
tion of ADH. It took until 1997 to formally recognize ADH as an
entity, and two patterns of onset were described, one presenting
in childhood and one with onset in adulthood.(4)
In the year 2000, mutations in the FGF23 gene were discov-
ered as the cause of ADH.(5) These FGF23 mutations (R176Q/W
and R179Q/W) replace Arg residues within a subtilisin-like pro-
protein convertase cleavage site (RXXR motif), leading to prote-
ase resistance of the intact FGF23 hormone and therefore
prolonging its half-life.(6) The cleavage site and its association
with the remarkable waxing and waning ADH phenotype has
since become the focus of interest. The unique “waxing/waning,”
“late-onset,” or “recurring” ADH manifestations soon lead to
speculation of a gene–environment association. In particular,
late onset disease in women with ADH suggested an association
with iron deﬁciency from menstrual blood loss or hormonal
interference.(4,7)
In 2011, Imel and colleagues(8) reported an apparent corre-
lation of the serum levels of iron and phosphate in symptom-
atic ADH patients, suggesting that iron deﬁciency increases
intact FGF23, a feature not seen in controls. Hence, iron deﬁ-
ciency, by a yet unknown gene–environment interaction
mechanism increases FGF23 expression, probably on a tran-
scriptional and posttranslational level. In the same year, these
human results were replicated in an ADH mouse model. ADH
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mice had elevated intact Fgf23 levels and hypophosphatemia
during iron deﬁciency, whereas wild-type controls maintained
normal serum intact Fgf23 and inorganic phosphate levels.
Also, bone Fgf23 mRNA and serum c-terminal Fgf23 were
induced in all mice during iron deﬁciency.(9) Further evidence
linking iron deﬁciency and FGF23 overexpression comes from
oral iron supplementation of anemic Gambian children where
ferritin concentrations negatively correlated with plasma
FGF23.(10)
In 2019, Liu and colleagues(11) published a report on six Chi-
nese ADH kindreds including 20 patients affected by R176Q/W
and R179Q/W mutations. They showed that at least seven of
the 11 symptomatic, hypophosphatemic patients were also iron
deﬁcient, and 90% were female. They also summarized all the
B
A
Fig. 1. Fourteen-year longitudinal observation of a female patient with ADH who ﬁrst presented at age 26 months with rickets and iron deﬁciency. (A)
Phosphorus metabolism; (B) the corresponding iron metabolism. Before starting oral iron, she received only conventional rickets therapy, which was fully
stopped at age 9.25 years. Continuous oral iron therapy is depicted as a dark box, and 3-month intermittent oral iron supplementation as a dashed box.
The vertical lines represent start and end of iron supplementation period. Analysis of all her biochemical data points revealed that serum phosphate cor-
related best with ferritin (r = 0.65, p = .003) and calcitriol concentrations (r = 0.62, p = .008).
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medical literature, which now includes only 13 documented ADH
kindreds, and found that patients with R179Q/W mutations
appeared to present earlier in life than those with R176Q/W
mutations, a ﬁnding that will have to be conﬁrmed over time.
Oral Iron Therapy Reverses the ADH Phenotype
In 2015, Kapelari and colleagues(12) were the ﬁrst to report an
iron-deﬁcient girl with ADH and active rickets whose phosphate
metabolism normalized and rickets fully healed on oral iron
treatment alongside normalization in ferritin levels, allowing for
rickets medication to be discontinued. In 2019, the Chinese
group(11) also reported improvement and normalization in phos-
phate metabolism in several symptomatic, iron-deﬁcient ADH
patients using oral iron therapy but did not provide comprehen-
sive treatment data.
In this issue of the Journal of Bone Mineral Research (JBMR),
Imel and colleagues(13) corroborate the role of oral iron in ADH
reversal in a well-conducted prospective study in ﬁve adults. Oral
iron doses were titrated to serum iron concentrations and
reached 130 to 260 mg/day at the end of the study. The study
is remarkable because, despite its small sample size (n = 5), it
depicts two distinctly different groups of patients. At baseline,
the three hypophosphatemic subjects with the highest FGF23
concentrations were iron deﬁcient and had a striking increase
in serum phosphorus concentrations in response to oral iron
therapy and only a mild increase in ferritin. This remarkable
response was much in contrast to the two subjects who at base-
line had normal FGF23, phosphorus, and ferritin levels and
showed no clinically meaningful response in phosphate or
FGF23 to iron therapy. These two subjects had been iron sufﬁ-
cient at baseline and demonstrated, in fact, a sharp and continu-
ous increase in serum ferritin during the study to levels over
200 μg/L, which raises concerns about iron overload if iron ther-
apy was to be continued. The WHO deﬁnes the criteria for iron
overload as serum ferritin concentrations over 150 and 200 μg/L
in females and males, respectively.(14)
Further Insights Into the Natural Course of
Disease
As far as evidence goes, iron deﬁciency constitutes a risk to
develop disease manifestations for patients with ADH and quite
likely explains the time of presentation in life, the spontaneous
healing, the late onset, and the relapses. Iron deﬁciency can
occur at any time in life and hence ADH also may become symp-
tomatic at any time. Seton & Jüppner(15) reported a woman who
was ﬁrst diagnosed with ADH at age 85 years; her history
indicated intermittently recurring disease from early childhood
diagnosis of rickets to bone pain from osteomalacia in adult-
hood; although her iron status at presentation was not docu-
mented she was not anemic. Of the 11 symptomatic subjects
in the Chinese series, seven were iron deﬁcient and two further
subjects were suspected to be deﬁcient.(11) Therefore, quite pos-
sibly, the intermittent hypophosphatemic manifestations in ADH
occur in synchrony with episodes of iron deﬁciency. However, to
date, we still know very little about modifying genes and how
exactly iron deﬁciency stimulates FGF23 mRNA expression.
Oral Iron Therapy: Long-Term Observation of the
Original Case
Here, we take the opportunity to share further longitudinal,
observational data on the original ADH case that ﬁrst demon-
strated the reversibility of hypophosphatemia on oral iron ther-
apy.(12) The girl had presented with hypophosphatemic rickets
and iron deﬁciency at age 26 months and was found to have a
typical R179Q mutation in FGF23. Rickets responded well to con-
ventional therapy. Only after high-dose oral iron therapy
(3.5 mg/kg/day) from age 8.1 years did her phosphate metabo-
lism normalize so that all rickets medication could be withdrawn.
As seen in Fig. 1A,B her serum phosphorus remained normal
while she was taking oral iron supplements intermittently as
per WHO guidelines(16,17) during her early pubertal years,
although her compliance was also erratic and her ferritin
remained relatively low. From her 14th birthday, just before her
menarche at age 14.2 years, she was taking regular supplemen-
tal iron (II) sulfate at a dose of 2.3 mg/kg/day (below the thera-
peutic dose of 3 to 6 mg/kg of elemental iron), and at her next
visit 8 months later her serum iron concentration was
68.6 μmol/L (383 μg/dL), transferrin saturation 85% (7% to
46%), levels possibly associated with iron toxicity, while her ferri-
tin was 20 μg/L.(18) Unconﬁrmed suspicion arose that she may
have deliberately taken higher doses prior to the consultation,
presumably to hide noncompliance; her iron supplements were
nevertheless stopped for safety reasons.
Eightmonths later, she presentedwith polymenorrhea, severe
hypophosphatemia (serum phosphate 0.25 mmol/L), and iron
deﬁciency without anemia (iron 6.9 μmol/L, transferrin satura-
tion 7%, ferritin 6 μg/L). Shewas once again restarted on oral iron
supplements (2 mg/kg/day) and serum phosphorus and renal
tubular phosphate reabsorption in mass per unit volume of glo-
merular ﬁltrate (TmP/GFR) improved. Nonetheless, polymenor-
rhea persisted and to date, age 16 years, neither serum
phosphorus nor ferritin have normalized on supplementation
despite improvement in iron status (Fig. 1), presumably due to
Table 1. Clinical Management of ADH Patients Depending on Iron Status
ADH risk groups Management Goal
Low-risk, normophosphatemic, normal
ferritin (iron-sufﬁcient)
Only monitoring Maintain normal ferritin levels
At risk, normophosphatemic, iron
sufﬁcient or deﬁcient, including
women of reproductive age
Oral iron supplementation (1-2 mg/kg
of elemental Fe) for 3 months/year
Maintain/reach normal ferritin levels,
avoid iron overload
Hypophosphatemic, iron deﬁcient
(with/without anemia), low ferritin
Oral iron treatment (3 to 6 mg/kg
elemental Fe, max 200 mg/day) for
3 months, followed by
supplementation
Reach normophosphatemia, avoid iron
toxicity and overload
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insufﬁcient iron dose in relation to heavymenstrual blood loss, or
compliance.
Spearman correlation analysis of all available biochemical
data over the 14-year observation period was performed to
assess the relationship of phosphate and iron metabolism. The
results show that serum phosphate was most closely correlated
to serum ferritin (r = 0.65, p = .003) and calcitriol (r = 0.62,
p = .008), not with serum iron or transferrin saturation (r = not
signiﬁcant [n.s.]). Similarly, TmP/GFR showed signiﬁcant correla-
tion only with ferritin (r = 0.54, p = .02) and calcitriol
(r = 0.62, p = .008).
Overall, evidence from these longitudinal observations clearly
indicates that iron deﬁciency triggers hypophosphatemia in
ADH, and that oral iron treatment reverses deﬁciencies in both
elements. In normophosphatemic ADH subjects, iron had no
effect on phosphate metabolism in the study by Imel and
colleagues,(13) so the direct correlation between elements only
exists during iron deﬁciency, which suggests that the lack of iron
must be the trigger to increased FGF23 mRNA expression. The
fact that most symptomatic patients are women during repro-
ductive age (90% in the Chinese cohort)(11) suggests that even
mild iron deﬁciency without anemia (ie, from hypermenorrhea
or polymenorrhea) serves as a trigger for FGF23 excess in ADH.
Oral Iron for Prevention and Treatment: the New
Management Strategy for ADH
Given this new evidence, what is the way forward in themanage-
ment of ADH patients? Iron deﬁciency is the most frequent
micronutrient deﬁciency globally, affecting one-third of non-
pregnant women.(17) Certain risk groups, such as individuals with
ADH, need to be regarded as at high risk of complications. The
strategy will undoubtedly have to be the avoidance and treat-
ment of iron deﬁciency, in order to maintain or re-establish nor-
mophosphatemia in ADH patients. Hence, in our view there are
three distinct groups of patients carrying FGF23 mutations,
judged by their ferritin status, with different proposed manage-
ment criteria (see Table 1):
• The ﬁrst group constitutes normophosphatemic and iron-
sufﬁcient ADH patients who require regular monitoring of
both elements but no regular iron supplements.
• The second group are normophosphatemic patients at risk of
iron deﬁciency, speciﬁcally all women during the reproductive
age, people on vegetarian or vegan diets, or with malabsorp-
tive or cardiac conditions, where preventative supplementa-
tion doses of oral iron are indicated. These should follow the
WHO guidance on iron supplementation.(16,17)
• The third group consists of hypophosphatemic ADH patients
who require oral iron in treatment doses (3 to 6 mg/kg of ele-
mental iron) until normophosphatemia is reached, followed by
the WHO supplementation regimen.
Oral iron therapy needs to be handled with caution. Careful
and regular monitoring of iron status is therefore recommended
in subjects with ADH, to avoid iron toxicity(18) and overload.(14)
During phases of hypophosphatemia, active vitamin D ana-
logues and oral phosphate can of course be given alongside iron
therapy. For subjects who do not tolerate or accept iron substitu-
tion, both conventional therapy as well as burosumab are avail-
able treatment options. As for all forms of hypomineralization,
25OH vitamin D should be kept in the normal range.
Evidence from the medical literature on oral iron therapy in
ADH,(11–13) including our long-term observation presented here,
indicate that ferritin, a marker of the body’s iron store, may be
the best indicator relevant to medical decision making. We
therefore propose ferritin as the main monitoring parameter by
which to judge the need for iron supplementation in ADH.
A Glimpse Into the Future
Preventing the manifestation of a genetic disease may appear to
be a strange concept speciﬁc to ADH. We propose that the main-
tenance of normal iron status, assessed by serum ferritin, should
be themainmonitoring target in subjects with known ADH. If the
existing evidence gained from the few kindreds worldwide is
corroborated, then prevention of hypophosphatemia with asso-
ciated rickets and osteomalacia should be possible.
For those newly diagnosed or with a relapse whose iron stores
are low (low ferritin, iron-deﬁciency anemia), the ﬁrst line of ther-
apy should be oral iron because a reversal of the phenotype and
reaching normophosphatemia should be possible if oral iron
therapy is tolerated and taken. Treatment with active vitamin D
analogues and oral phosphate may be reserved to those not
accepting or tolerating oral iron. Intravenous iron preparations,
speciﬁcally ferric carboxymaltose, can cause severe and
prolonged hypophosphatemia and osteomalacia(19) and thus
should be avoided in ADH.
For an ultrarare disease such as ADH, evidence and clinical
experience is hard to come by. International registries for rare
bone diseases are the only way forward to gain systematic new
evidence from patients. We call on the international community
to join these registries.
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